The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients.

For more information please visit http://www.idorsia.com

Products, services, technology

We have four phase 3 products: daridorexant (insomnia), clazosentan (treatment of vasospasm following a sub-arachnoid subarachnoid hemorrhage), aprocitentan (difficult to treat hypertension) and lucerastat (Fabry's disease). Our pipeline has 12 assets in total. Link

Location
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    >250
Key business